Humana’s (HUM) “Neutral” Rating Reiterated at Cantor Fitzgerald

Humana (NYSE:HUM)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $395.00 price objective on the insurance provider’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 20.36% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Oppenheimer lifted their price target on shares of Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Baird R W raised shares of Humana to a “hold” rating in a research report on Thursday, May 30th. Morgan Stanley began coverage on shares of Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price objective on the stock. Royal Bank of Canada raised their price objective on shares of Humana from $385.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, September 5th. Finally, TD Cowen raised their price objective on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $398.70.

Humana Price Performance

Shares of HUM stock opened at $328.19 on Tuesday. Humana has a 52-week low of $298.61 and a 52-week high of $530.54. The stock has a market cap of $39.51 billion, a PE ratio of 20.44, a PEG ratio of 2.80 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm’s 50 day moving average price is $365.82 and its two-hundred day moving average price is $347.21.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same period last year, the firm earned $8.94 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, analysts forecast that Humana will post 16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Mendota Financial Group LLC increased its stake in shares of Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after purchasing an additional 27 shares during the last quarter. Aurora Investment Counsel raised its holdings in Humana by 1.3% in the 4th quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after acquiring an additional 29 shares during the period. Capital Advisors Ltd. LLC lifted its position in Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after acquiring an additional 31 shares during the last quarter. EP Wealth Advisors LLC boosted its holdings in shares of Humana by 1.6% during the fourth quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock worth $1,050,000 after acquiring an additional 37 shares during the period. Finally, CarsonAllaria Wealth Management Ltd. grew its position in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.